Pattern of intravenous bisphosphonate use in outpatient care in Germany

Pharmacoepidemiology and Drug Safety

Volumn 17, Issue 9, 2008, Pages 896-903

  Hoffmann, Falk ^a   Jung, Tatjana I ^b   Felsenberg, Dieter ^b   Glaeske, Gerd ^a  

^a UNIVERSITY OF BREMEN   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Bisphosphonates; Epidemiology; Germany; Osteonecrosis of the jaw; Zoledronic acid

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; IBANDRONIC ACID; PAMIDRONIC ACID; ZOLEDRONIC ACID;

ADULT; ARTICLE; BONE NECROSIS; CANCER SURVIVAL; COHORT ANALYSIS; DRUG EXPOSURE; DRUG UTILIZATION; FEMALE; GERMANY; HUMAN; LIFE EXPECTANCY; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; OUTPATIENT CARE; PRESCRIPTION; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; SEX DIFFERENCE; SINGLE DRUG DOSE; SURVIVAL RATE; TREATMENT DURATION; TREND STUDY;

ADULT; AGED; AGED, 80 AND OVER; AMBULATORY CARE; BONE DENSITY CONSERVATION AGENTS; COHORT STUDIES; DIPHOSPHONATES; DRUG UTILIZATION; FEMALE; GERMANY; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED;

EID: 52949108787     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.1634     Document Type: Article

References (25)

1. Pavlakis N, Schmidt R, Stockler M. Bisphosphonates for breast cancer. Cochrane Database Syst Rev 2005; 3: CD003474.
2. Wong R, Wiffen PJ. Bisphosphonates for the relief of pain secondary to bone metastases. Cochrane Database Syst Rev 2002; 2: CD002068.
3. Yuen KK, Shelley M, Sze WM, Wilt T, Mason MD. Bisphosphonates for advanced prostate cancer. Cochrane Database Syst Rev 2006; 4: D006250.
4. Lacy MQ, Dispenzieri A, Gertz MA, et al. Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma. Mayo Clin Proc 2006; 81(8): 1047-1053.
5. Body JJ, Coleman R, Clezardin P, Ripamonti C, Rizzoli R, Aapro M. International Society of Geriatric Oncology (SIOG) clinical practice recommendations for the use of bisphosphonates in elderly patients. Eur J Cancer 2007; 43(5): 852-858.
6. Migliorati CA, Siegel MA, Elting LS. Bisphosphonate-associated osteonecrosis: a long-term complication of bisphosphonate treatment. Lancet Oncol 2006; 7(6): 508-514.
7. Walsh JP, Attewell R, Stuckey BG, et al. Treatment of Paget's disease of bone: a survey of clinical practice in Australia. Bone 2008; 42(6): 1219-1225.
8. Black DM, Delmas PD, Eastell R, et al. HORIZON Pivotal Fracture Trial. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007; 356(18): 1809-1822.
9. Van den Wyngaert T, Huizing MT, Vermorken JB. Osteonecrosis of the jaw related to the use of bisphosphonates. Curr Opin Oncol 2007; 19(4): 315-322.
10. Badros A, Weikel D, Salama A, et al. Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors. J Clin Oncol 2006; 24(6): 945-952.
11. Bamias A, Kastritis E, Bamia C, et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol 2005; 23(34): 8580-8587.
12. Jung TI, von der Gablentz J, Hoffmeister B, et al. Osteonecrosis of jaw under bisphosphonate therapy: patient profile and risk assessment. J Bone Miner Res 2007; 22: S113.
13. Wilkinson GS, Kuo YF, Freeman JL, Goodwin JS. Intravenous bisphosphonate therapy and inflammatory conditions or surgery of the jaw: a population-based analysis. J Natl Cancer Inst 2007; 99(13): 1016-1024.
14. Durie BG, Katz M, Crowley J. Osteonecrosis of the jaw and bisphosphonates. N Engl J Med 2005; 353(1): 99-102.
15. Woo SB, Hellstein JW, Kalmar JR. Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 2006; 144(10): 753-761.
16. Schneeweiss S, Avorn J. A review of uses of health care utilization databases for epidemiologic research on therapeutics. J Clin Epidemiol 2005; 58(4): 323-337.
17. Tobi H, van den Berg PB, de Jong-van den Berg LT. Small proportions: what to report for confidence intervals? Pharmacoepidemiol Drug Saf 2005; 14(4): 239-247.
18. Federal Statistical Office. Statistical Yearbook 2006. For the Federal Republic of Germany. Federal Statistical Office: Wiesbaden, 2006.
19. Diel IJ, Fogelman I, Al-Nawas B, et al. Pathophysiology, risk factors and management of bisphosphonate-associated osteonecrosis of the jaw: is there a diverse relationship of amino- and non-aminobisphosphonates? Crit Rev Oncol Hematol 2007; 64(3): 198-207.
20. Wang EP, Kahan LB, Strewler GJ, Raje N, Troulis MJ. Incidence of osteonecrosis of the jaw in patients with multiple myeloma and breast or prostate cancer on intravenous bisphosphonate therapy. J Oral Maxillofac Surg 2007; 65(7): 1328-1331.
21. Erkens JA, Panneman MM, Klungel OH, van den Boom G, Prescott MF, Herings RM. Differences in antihypertensive drug persistence associated with drug class and gender: a PHARMO study. Pharmacoepidemiol Drug Saf 2005; 14(11): 795-803.
22. Penning-van Beest FJ, Goettsch WG, Erkens JA, Herings RM. Determinants of persistence with bisphosphonates: a study in women with postmenopausal osteoporosis. Clin Ther 2006; 28(2): 236-242.
23. Lewiecki EM, Babbitt AM, Piziak VK, Ozturk ZE, Bone HG. Adherence to and gastrointestinal tolerability of monthly oral or quarterly intravenous ibandronate therapy in women with previous intolerance to oral bisphosphonates: a 12-month, open-label, prospective evaluation. Clin Ther 2008; 30(4): 605-621.
24. Andrade SE, Kahler KH, Frech F, Chan KA. Methods for evaluation of medication adherence and persistence using automated databases. Pharmacoepidemiol Drug Saf 2006; 15(8): 565-574.
25. Khosla S, Burr D, Cauley J, et al. American Society for Bone and Mineral Research. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2007; 22(10): 1479-1491.